First-in-human Study of ATX-898, as Monotherapy and in Combination With Other Anti-neoplastic Agents, in Participants With Advanced Solid Tumors

Study Identifier:
ATX-898-101
CT.gov Identifier:
EudraCT Identifier:
EU Trial (CTIS) Number:
Study Contact Information:
Recruiting

Considering participating in a START clinical trial?

Study Summary

Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study consists of 2 parts. Part 1 evaluates ATX-898 as monotherapy and Part 2 evaluates ATX-898 in combination with anti-neoplastic agents of interest. Both parts will consists of a dose escalation portion and a dose expansion portion.

Main objective (English)

Part 1A: Evaluate the overall safety and tolerability of ATX-898 administered as monotherapy and determine the MTD (or maximum tested dose) and recommended dose for expansion (RDE); Part 1B: Assess the antitumor activity of ATX-898 administered as monotherapy in participants in each expansion cohort; Part 2A: Determine the RDE of ATX-898 in combination with fulvestrant and abemaciclib (Part 2A1) and/or fulvestrant and ribociclib (Part 2A2); Part 2B: Further assess the antitumor activity of ATX-898 at the combination RDE in combination with fulvestrant and abemaciclib (Part 2B1) and/or ribociclib (Part 2B2)

Clinical Study Information for Healthcare Providers

By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

Study Locations

Location
Investigator
Status
Condition(s) Treated at Site
Location
START Barcelona
Barcelona, Spain, 08023
Investigator
Tatiana Hernandez Guerrero
Status
Recruiting
Condition(s) Treated at Site
Solid Tumor
Location
START Madrid, Spain (CIOCC)
Madrid, Spain, 28050
Investigator
Irene Moreno
Status
Recruiting
Condition(s) Treated at Site
Solid Tumor
Location
START Dallas Fort Worth
Fort Worth, TX, United States, 76104
Investigator
Henry Xiong
Status
Recruiting
Condition(s) Treated at Site
Solid Tumor
Location
START Madrid, Spain (FJD)
Madrid, Spain, 28040
Investigator
Miriam Dorta Suarez
Status
Will Be Recruiting
Condition(s) Treated at Site
Solid Tumor
Location
START Mountain Region
West Valley City, UT, United States, 84119
Investigator
William McKean
Status
Recruiting
Condition(s) Treated at Site
Solid Tumor
Location
START San Antonio
San Antonio, TX, United States, 78229
Investigator
Amita Patnaik
Status
Recruiting
Condition(s) Treated at Site
Solid Tumor